India's generic semaglutide rush slashes prices but raises safety alarms
The global market for weight-loss injections is shifting rapidly after patent protections for semaglutide—the key ingredient in Ozempic and Wegovy—expired last week. In India, over 40 pharmaceutical firms have already launched or are preparing to release generic versions, with prices dropping sharply. This surge in availability has sparked both demand and concern over safety and regulation. The first generic semaglutide injections hit the Indian market over the weekend, just days after the patent expired on March 20. Major manufacturers like Sun Pharma, Dr. Reddy's, Cipla, and Biocon are now selling the drugs, alongside smaller firms such as Natco, which offers vials and pens starting at around 14 USD per month. With competition intensifying, monthly costs in India have fallen to between 15 and 35 Swiss francs—roughly half the previous price.
India's role as a production hub for these medications is growing, but its poorly regulated pharmaceutical sector raises risks. The country has faced repeated scandals involving adulterated drugs, and experts warn that the rush to meet demand could worsen quality control issues. Despite this, individuals can legally purchase a one-month supply in India and bring it into Switzerland for personal use. Swissmedic, Switzerland's drug regulatory agency, has cautioned against importing such products. The agency highlights the dangers of counterfeit or substandard medications, which could pose serious health risks. Meanwhile, India's obesity crisis is driving demand, with projections suggesting nearly 450 million people could be severely obese by 2050. Changing beauty standards and health concerns are also fuelling interest in weight-loss treatments.
The expiration of semaglutide's patent has triggered a wave of low-cost generics in India, making weight-loss injections more accessible. However, the lack of strict oversight and past incidents of drug adulteration create significant safety concerns. As prices continue to drop, regulators and consumers alike face growing challenges in ensuring product quality and proper use.
